Adverum Biotechnologies Inc
Company Profile
Business description
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Contact
100 Cardinal Way
Redwood CItyCA94063
USAT: +1 650 659-9323
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
155
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,786.70 | 13.10 | 0.15% |
| CAC 40 | 7,557.31 | 0.85 | -0.01% |
| DAX 40 | 23,649.30 | 150.97 | 0.64% |
| Dow JONES (US) | 43,386.84 | 404.41 | 0.94% |
| FTSE 100 | 8,735.60 | 16.85 | 0.19% |
| HKSE | 24,357.21 | 31.81 | 0.13% |
| NASDAQ | 20,167.91 | 194.36 | 0.97% |
| Nikkei 225 | 40,215.36 | 630.78 | 1.59% |
| NZX 50 Index | 12,544.91 | 64.86 | 0.52% |
| S&P 500 | 6,141.02 | 48.86 | 0.80% |
| S&P/ASX 200 | 8,556.80 | 6.00 | 0.07% |
| SSE Composite Index | 3,443.62 | 4.83 | -0.14% |